Acquiring Company
AbbVie Inc.
Acquired Company
Syndesi Therapeutics
North ChicagoManufacturingBiotechnologyHealthcareHealth CareTherapeuticsNon ProfitPharmaceuticalBiopharmaSoftwareDescription
AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder.
Quick answer
AbbVie Inc. is acquiring Syndesi Therapeutics, announced March 1, 2022. AbbVie Inc. is based in North Chicago, Illinois, United States.
- How much did AbbVie Inc. pay for Syndesi Therapeutics?
- The deal value was not disclosed.
- What does AbbVie Inc. do?
- Venture capital subsidiary of Abbvie
- Where are AbbVie Inc. and Syndesi Therapeutics based?
- AbbVie Inc. is based in North Chicago, Illinois, United States.
- Who are the decision-makers at AbbVie Inc?
- Fundz holds 2 contacts at AbbVie Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Halozyme To Acquire Antares Pharma To Create A Specialty Product And Drug Delivery Leader (April 13, 2022)
- Masimo Closes Acquisition Of Sound United (April 12, 2022)
- Pfizer To Acquire Reviral And Its Respiratory Syncytial Virus Therapeutic Candidates (April 7, 2022)
- Pfizer Completes Acquisition Of Arena Pharmaceuticals (March 11, 2022)
- Clarify Health Acquires Embedded Healthcare To Scale Value-Based Care For Health Plans (March 14, 2022)
- Asymchem Acquires Snapdragon Chemistry (February 11, 2022)
Who to call at AbbVie Inc., and when
When AbbVie Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day AbbVie Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AbbVie Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AbbVie Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Syndesi Therapeutics?
Syndesi Therapeutics was acquired by AbbVie Inc., based in North Chicago. The deal was reported on March 1, 2022. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire Syndesi Therapeutics?
AbbVie Inc.'s acquisition of Syndesi Therapeutics was reported on March 1, 2022. AbbVie (NYSE: ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Syndesi Therapeutics do?
Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. It is privately held, operating in Software.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.